尼拉帕尼 尼拉帕尼是一种聚ADP核糖聚合酶（PARP）抑制剂，适用于： 1、成年晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌症患者的维持治疗，这些患者对一线基于铂的化疗有完全或部分反应。

Niraparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor used to treat certain types of ovarian cancer and prostate cancer.

Indications

• Ovarian cancer : For first-line maintenance treatment of patients with advanced ovarian cancer who have achieved complete or partial remission after receiving platinum-based chemotherapy.

• Prostate cancer : combined with prednisone or prednisolone, it is indicated for adult patients with metastatic castration-resistant prostate cancer (mCRPC) carrying germline and/or somatic BRCA gene mutations.

Dosage

• Ovarian cancer : The specific dose should be determined based on the patient's weight and platelet count. It is recommended to be used under the guidance of a doctor.

• Prostate cancer : Each tablet contains 50 mg of niraparib and 500 mg of abiraterone. The specific usage and dosage should follow the doctor's prescription.

Adverse Reactions

The most common adverse reactions in patients treated with niraparib in clinical trials included:

• Nausea (65%)

• Thrombocytopenia (60%)

• Anemia (56%)

• Fatigue (55%)

• Constipation (39%)

• Musculoskeletal pain (36%)

• Abdominal pain (35%)

• Vomiting (33%)

• Neutropenia (31%)

• Decreased appetite (24%)

• Leukopenia (24%)

• Insomnia (23%)

• Headache (23%)

• Dyspnea (22%)

• Rash (21%)

• Diarrhea (18%)

• Hypertension (17%)

• Cough (16%)

• Dizziness (14%)

• Acute kidney injury (13%)

• Urinary tract infection (12%)

• Hypomagnesemia (11%)

Patients should regularly monitor blood routine and liver and kidney function indicators while using niraparib.

Precautions

• Bone marrow suppression : Niraparib may cause bone marrow suppression, including thrombocytopenia, anemia, and neutropenia. It is recommended to perform blood routine examinations before and regularly during treatment.

• Hypertension and tachycardia : Hypertension and tachycardia may occur during treatment, and regular monitoring of blood pressure and heart rate is recommended.

• Embryo-fetal toxicity : Niraparib may cause fetal harm and should be avoided by pregnant women. Women of childbearing age should take effective contraceptive measures during treatment.

Contraindications

• Niraparib is contraindicated in patients with hypersensitivity to niraparib or any of its components.

• It is contraindicated for pregnant and lactating women.

Drug interactions

Niraparib is primarily metabolized by the liver and may interact with other medications when used simultaneously. Consult your doctor or pharmacist before starting a new medication.

Storage conditions

This product should be stored below 25°C away from moisture and direct sunlight.

Please read the drug instructions carefully before use and follow the doctor's instructions for treatment.